Editas Medicine, Inc. Common Stock EDIT

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

• GlobeNewswire Inc. 8 sept

  Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

  Editas Medicine announced the appointment of Dan Ory, M.D., as Chief Medical Officer effective September 8, 2026. Dr. Ory brings over 25 years of experience in cardiovascular and genetic medicine, previously serving as CMO at Arbor Biotechnologies and Casma Therapeutics. He will oversee clinical development strategy as Editas advances EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia treatment, toward clinical trials.

  

• GlobeNewswire Inc. 14 jul

  Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases

  Lyora Therapeutics, a new biotech company focused on genetic medicines for inherited retinal diseases, launched with $2.5 million in seed funding. The company's lead programs include LYA-101 for retinitis pigmentosa and LYA-102 for Usher Syndrome Type 2, with plans to submit an IND for LYA-101 within 18 months. The company is led by experienced executives from major genetic medicine firms and co-founded by renowned ophthalmology researchers.

  

• GlobeNewswire Inc. 3 jul

  Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

  The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.

  

• GlobeNewswire Inc. 3 jul

  Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

  The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.